MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion

    R. Hauser, A. Videnovic, P. Odin, K. Chaudhuri, M. Shah, J. Homola, L. Bergmann, R. Gupta, O. Vaou (Tampa, USA)

    Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • 2025 International Congress

    The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

    I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

    Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…
  • 2025 International Congress

    Efficacy of LSVT-BIG Treatment Compared to Other Physiotherapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    A. Amin, M. Helal, A. Alsokery, H. Sabet, A. Ibrahim, A. Suleiman, I. Yakout, A. Abunamoos, M. Elsayed (Cairo, Egypt)

    Objective: We aim is to assess the efficacy of Lee Silverman Voice Treatment-BIG therapy (LSVT-BIG) compared to other physiotherapy in patients with Parkinson's Disease (PwP).…
  • 2025 International Congress

    The Benefits of Whole-Body Electro Muscle Stimulation (WB-EMS) in a patient with Parkinson’s Disease

    N. Duff, C. Cawood, M. Noble (Parktown, South Africa)

    Objective: To determine the motor and non-motor benefits of WB-EMS in a patient with Parkinson’s disease Background: Parkinson’s disease causes both motor and non-motor symptoms.…
  • 2025 International Congress

    A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…
  • 2025 International Congress

    Relationship Between Improvement in “On” Time, Nonmotor Symptoms, and Quality of Life in Adults Treated With Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease

    K. Chaudhuri, P. Odin, J. Aldred, L. Bergmann, J. Homola, R. Gupta, A. Antonini, M. Soileau (Spokane, USA)

    Objective: To determine if adults with advanced Parkinson’s disease (aPD) treated with a 24‑hour/day continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion who had ≥ 1‑hour improvement in…
  • 2025 International Congress

    Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

    M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

    Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…
  • 2025 International Congress

    Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease

    R. Pahwa, Z. Mari, W. Ondo, L. Harmer, A. Lind, R. Hauser (Kansas City, USA)

    Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…
  • 2025 International Congress

    SL-START: A Multicentre Observational Study of Sublingual Apomorphine Titration and Usage Schemes in Routine Practice

    J. Kassubek, P. Themann, H. Brigas, C. Maganete, G. Harrison-Jones, I. Pijuan Jiménez (Ulm, Germany)

    Objective: A patient’s early experience with a new medication is critical to medication adherence and overall treatment outcomes. The SL-START study aims to characterize how…
  • « Previous Page
  • 1
  • …
  • 323
  • 324
  • 325
  • 326
  • 327
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley